C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy

European Journal of Heart Failure

Volumn 6, Issue 6, 2004, Pages 731-734

  Sliwa, Karen ^a   Woodiwiss, Angela ^b   Libhaber, Elena ^a   Zhanje, Fitzgerald ^a   Libhaber, Carlos ^a   Motara, Riaz ^a   Essop, Rafique ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARVEDILOL; DIGOXIN; ENALAPRIL; FUROSEMIDE; IMMUNOMODULATING AGENT; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORRELATION ANALYSIS; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL;

ANTIGENS, CD95; C-REACTIVE PROTEIN; CARDIOMYOPATHY, DILATED; HUMANS; PENTOXIFYLLINE; PREDICTIVE VALUE OF TESTS; SYSTOLE; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 7944223097     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2003.11.006     Document Type: Article

References (16)

1. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., Sareli P. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 351:1998;1091-1093
2. Skudicky D., Bergemann A., Sliwa K., Candy G., Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor and carvedilol. Results of a randomized study. Circulation. 103:2001;1083
3. Sliwa K., Woodiwiss A., Candy G., Badenhorst D., Libhaber C., Norton G., et al. Pentoxifylline modifies cytokine profiles and improves left ventricular performance in patients with decompensated congestive heart failure. Am J Cardiol. 90:2002;118-122
4. Neuner P., Klosner G., Schauer E., Pourmojib M., Macheier W., Grunwald C., et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology. 83:1994;262-267
5. Schadene L., Vandenbussche P., Crusiaux A., Schwarz T. Differential effects of pentoxifylline on the production of TNF-alpha and IL-6 monocytes and T cells. Immunology. 75:1992;30-40
6. Weinberg J.B., Mason S.N., Wortham T.S. Inhibition of TNF-alpha and interleukin-1 beta messenger RNA expression in HL-60 leukaemia cells by pentoxifylline and dexamethasone. Blood. 79:1992;3337-3343
7. D'Hellencourt C.L., Diaw L., Cornillet P., Guenounou M. Differential regulation of TNF-alpha, IL-beta, IL-6, IL-8, TNF-beta, and IL-10 by pentoxifylline. Int Immunopharmacol. 18:1996;739-748
8. Skudicky D., Sliwa K., Bergemann A., et al. Reduction in Fas/Apo-1 plasma levels correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline: results of a randomized trial. Heart. 84:2000;438-441
9. Sato Y., Takatsu Y., Kataoka K., Yamada T., Taniguchi R., Sasayama S., et al. Serial circulating concentrations of C-reactive protein, interleukin-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 22:1999;811-813
10. Kanebo K., Kanada T., Yamauchi Y., Hasegawa A., Iwasaki T., Arai M., et al. C-reactive protein in dilated cardiomyopathy. Cardiology. 91:1999;215-219
11. Dibbs Z., Thornby J., White B.G., Mann D.L. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. Am J Cardiol. 33:1999;1935-1942
12. Meier-Ewert H.K., Ridker P.M., Rifai N., Prince N., Dinges D.F., Mullington J.M. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 47:2001;426-430
13. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., Stanek E. Variability and classification accuracy of serial high sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 47:2001;444-450
14. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Immunolgy. 38:2001;189-197
15. Barna B.P., Thomassen M.J., Clements M., Rankin D., Ahmed M. Cytokine induction associated with human C-reactive protein. Fed Am Soc Exp Biol J. 3:1989;284-285
16. Vetter M.L., Gerwurz H., Hansen B., James K., Baum L.L. Effects of C-reactive protein on human lymphocyte responsiveness. J Immunol. 130:1983;2121-2126